Gyre Therapeutics (GYRE) Competitors $7.76 -0.44 (-5.37%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$7.76 0.00 (-0.06%) As of 08/26/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. BHC, KYMR, SRRK, AMRX, XENE, CRNX, HCM, RARE, MOR, and ARWRShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Bausch Health Cos Kymera Therapeutics Scholar Rock Amneal Pharmaceuticals Xenon Pharmaceuticals Crinetics Pharmaceuticals HUTCHMED Ultragenyx Pharmaceutical MorphoSys Arrowhead Pharmaceuticals Gyre Therapeutics (NASDAQ:GYRE) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has more risk and volatility, GYRE or BHC? Gyre Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Do analysts rate GYRE or BHC? Gyre Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 131.96%. Bausch Health Cos has a consensus price target of $9.00, suggesting a potential upside of 25.44%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gyre Therapeutics is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings & valuation, GYRE or BHC? Gyre Therapeutics has higher earnings, but lower revenue than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M7.07$12.09M$0.01776.00Bausch Health Cos$9.63B0.28-$46M$0.2627.60 Is GYRE or BHC more profitable? Gyre Therapeutics has a net margin of 4.08% compared to Bausch Health Cos' net margin of 0.99%. Gyre Therapeutics' return on equity of 7.67% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics4.08% 7.67% 6.19% Bausch Health Cos 0.99%-852.36%5.25% Do insiders & institutionals believe in GYRE or BHC? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 8.1% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to GYRE or BHC? In the previous week, Bausch Health Cos had 10 more articles in the media than Gyre Therapeutics. MarketBeat recorded 15 mentions for Bausch Health Cos and 5 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.86 beat Bausch Health Cos' score of 0.11 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGyre Therapeutics beats Bausch Health Cos on 12 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$789.77M$3.07B$5.73B$9.74BDividend YieldN/A2.26%3.95%4.07%P/E Ratio776.7820.5230.3326.09Price / Sales7.07352.27446.43115.97Price / Cash41.5244.2437.7259.08Price / Book5.798.139.776.67Net Income$12.09M-$54.08M$3.27B$265.43M7 Day Performance0.39%4.48%3.64%3.36%1 Month Performance1.57%3.64%3.80%0.39%1 Year Performance-37.37%7.34%31.94%19.43% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics1.2654 of 5 stars$7.76-5.4%$18.00+132.0%-44.7%$789.77M$105.76M776.7840Analyst ForecastBHCBausch Health Cos4.5517 of 5 stars$8.02-3.8%$9.00+12.2%+20.2%$3.09B$9.63B30.8520,700Analyst RevisionKYMRKymera Therapeutics2.9838 of 5 stars$43.62+2.3%$59.11+35.5%-11.8%$3.05B$47.07M-12.57170Positive NewsSRRKScholar Rock4.56 of 5 stars$31.52+0.4%$45.14+43.2%+258.6%$3.02B$33.19M-10.83140Positive NewsAMRXAmneal Pharmaceuticals3.0469 of 5 stars$9.26-2.0%$11.60+25.3%+10.7%$2.97B$2.85B926.938,100Positive NewsInsider TradeXENEXenon Pharmaceuticals2.1213 of 5 stars$37.82-1.1%$53.20+40.7%-5.3%$2.95B$7.50M-10.65210Positive NewsCRNXCrinetics Pharmaceuticals3.6291 of 5 stars$29.74-3.2%$68.86+131.5%-41.8%$2.89B$1.04M-7.24210Positive NewsInsider TradeHCMHUTCHMED2.6485 of 5 stars$16.43-0.1%$28.00+70.4%-9.0%$2.87B$602.20M0.001,811News CoverageRAREUltragenyx Pharmaceutical4.6695 of 5 stars$29.70+0.0%$81.50+174.4%-48.2%$2.86B$610.16M-5.371,294MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsARWRArrowhead Pharmaceuticals3.7543 of 5 stars$19.91-2.9%$43.14+116.7%-14.3%$2.84B$3.55M-15.55400Positive News Related Companies and Tools Related Companies Bausch Health Cos Competitors Kymera Therapeutics Competitors Scholar Rock Competitors Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors HUTCHMED Competitors Ultragenyx Pharmaceutical Competitors MorphoSys Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access